title: The selective cholecystokininB receptor antagonist L-365,260 diminishes the expression of naloxone-induced morphine withdrawal symptoms in normal and neuropathic rats.
abstract: The ability of a pretreatment with the cholecystokininB-receptor (CCK[B]) antagonist L-365,260 to prevent the development of morphine dependence was studied in normal and neuropathic (unilateral peripheral neuropathy) rats. A 4-day pretreatment regimen with two daily s.c. injections of either saline+saline, saline+morphine (3.0 mg/kg) or L-365,260 (0.2 mg/kg)+morphine was used, and withdrawal was precipitated by an injection of naloxone (1.0 or 2.0 mg/kg i.v.) at 24 h after the last pretreatment injection. After pretreatment with morphine alone, physical dependence developed in both normal and neuropathic rats. However, the incidence of teeth chattering and ptosis was higher in neuropathic rats. Pretreatment with the combination of L-365,260 and morphine prevented the expression of teeth chattering, ptosis, diarrhea, writhing and piloerection, but was devoid of effects on the exploratory activity among both groups of rats. These results suggest that endogenous CCK acting on CCK(B)-receptors may be involved in the development of morphine dependence both in normal and neuropathic rats.
authors.affiliation: Unité de Recherches de Physiopharmacologie du Système Nerveux, I.N.S.E.R.M. U-161, Paris, France. kayser@broca.inserm.fr
authors.forename: V
authors.initials: V
authors.lastname: Kayser
authors.forename: J J
authors.initials: JJ
authors.lastname: Idänpään-Hekkilä
authors.forename: D
authors.initials: D
authors.lastname: Christensen
authors.forename: G
authors.initials: G
authors.lastname: Guilbaud
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009020:Morphine / Q000009:adverse effects*; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology; D010523:Peripheral Nervous System Diseases / Q000150:complications*; D010671:Phenylurea Compounds; D051381:Rats; D017207:Rats, Sprague-Dawley; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D013375:Substance Withdrawal Syndrome / Q000150:complications / Q000188:drug therapy*
chemical_list: D001570:Benzodiazepinones; D009292:Narcotic Antagonists; D010671:Phenylurea Compounds; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D009270:Naloxone; C058121:L 365260; D009020:Morphine